Merck is racing to be first on the market among contenders in the PD-1 field of cancer therapy, and the European Medicines Agency has agreed to review its pembrolizumab as a treatment for advanced melanoma.

…read more

Source: Merck takes to Europe with its promising PD-1 cancer drug


0 No comments